RAS modulation prevents progressive cognitive impairment after experimental stroke: a randomized, blinded preclinical trial

BACKGROUND: With the aging population, the prevalence and incidence of cerebrovascular disease will continue to rise, as well as the number of individuals with vascular cognitive impairment/dementia (VCID). No specific FDA-approved treatments for VCID exist. Although clinical evidence supports that...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmed, Heba A., Ishrat, Tauheed, Pillai, Bindu, Fouda, Abdelrahman Y., Sayed, Mohammed A., Eldahshan, Wael, Waller, Jennifer L., Ergul, Adviye, Fagan, Susan C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090822/
https://www.ncbi.nlm.nih.gov/pubmed/30103772
http://dx.doi.org/10.1186/s12974-018-1262-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090822/
https://www.ncbi.nlm.nih.gov/pubmed/30103772
http://dx.doi.org/10.1186/s12974-018-1262-x

Ejemplares similares